These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 17717427)
1. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S Tumour Biol; 2007; 28(4):212-20. PubMed ID: 17717427 [TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475 [TBL] [Abstract][Full Text] [Related]
3. Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S Anticancer Res; 2018 Nov; 38(11):6399-6404. PubMed ID: 30396964 [TBL] [Abstract][Full Text] [Related]
4. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Bendardaf R; Lamlum H; Ristamäki R; Syrjänen K; Pyrhönen S Oncol Rep; 2008 Nov; 20(5):999-1004. PubMed ID: 18949393 [TBL] [Abstract][Full Text] [Related]
5. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer. Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736 [TBL] [Abstract][Full Text] [Related]
6. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Ohrling K; Edler D; Hallström M; Ragnhammar P Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Ma S; Egyházi S; Ringborg U; Hansson J Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066 [TBL] [Abstract][Full Text] [Related]
9. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Son BH; Ahn SH; Ko CD; Ka IW; Gong GY; Kim JC Breast J; 2004; 10(1):20-6. PubMed ID: 14717755 [TBL] [Abstract][Full Text] [Related]
10. Loss of protein expression of hMLH1 and hMSH2 with double primary carcinomas of the stomach and colorectum. Yamamoto M; Taguchi K; Baba H; Endo K; Kohnoe S; Okamura T; Maehara Y Oncol Rep; 2006 Jul; 16(1):41-7. PubMed ID: 16786121 [TBL] [Abstract][Full Text] [Related]
11. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry detects mismatch repair gene defects in colorectal cancer. Hameed F; Goldberg PA; Hall P; Algar U; van Wijk R; Ramesar R Colorectal Dis; 2006 Jun; 8(5):411-7. PubMed ID: 16684085 [TBL] [Abstract][Full Text] [Related]
13. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C; Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036 [TBL] [Abstract][Full Text] [Related]
14. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399 [TBL] [Abstract][Full Text] [Related]
15. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment. Vageli DP; Zaravinos A; Daniil Z; Dahabreh J; Doukas SG; Spandidos DA; Gourgoulianis KI; Koukoulis GK Int J Biol Markers; 2013 Jan; 27(4):e400-4. PubMed ID: 22865300 [TBL] [Abstract][Full Text] [Related]
16. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278 [TBL] [Abstract][Full Text] [Related]
17. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Brueckl WM; Moesch C; Brabletz T; Koebnick C; Riedel C; Jung A; Merkel S; Schaber S; Boxberger F; Kirchner T; Hohenberger W; Hahn EG; Wein A Anticancer Res; 2003; 23(2C):1773-7. PubMed ID: 12820457 [TBL] [Abstract][Full Text] [Related]
18. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Jacob S; Aguado M; Fallik D; Praz F Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654 [TBL] [Abstract][Full Text] [Related]